Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

Lipella Pharmaceuticals Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PITTSBURGH , SEPT. 15, 2025 /PRNEWSWIRE/ -- LIPELLA PHARMACEUTICALS INC.(OTC: LIPO) ("LIPELLA" OR THE "COMPANY"), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING CARE WITH INNOVATIVE MUCOSAL DELIVERY SOLUTIONS, TODAY ANNOUNCED THAT JONATHAN KAUFMAN, CHIEF EXECUTIVE OFFICER OF LIPELLA, WILL PRESENT A CORPORATE OVERVIEW AND FINAL RESULTS FROM PHASE 2A TRIAL OF LP-10 IN ORAL LICHEN PLANUS AT THE ZACKS SCR LIFE SCIENCES VIRTUAL INVESTOR FORUM ON SEPTEMBER 18TH, 2025 AT 12:30PM EDT.

LIPELLA PHARMACEUTICALS TO PRESENT AT ZACKS SCR LIFE SCIENCES VIRTUAL INVESTOR FORUM AND REPORT FINAL PHASE 2A RESULTS IN ORAL LICHEN PLANUS

PITTSBURGH, JUNE 25, 2025 (GLOBE NEWSWIRE) -- LIPELLA PHARMACEUTICALS INC. (OTC: LIPO) (LIPELLA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING THERAPIES FOR DISEASES WITH SIGNIFICANT UNMET NEED, TODAY ISSUED A LETTER FROM CHIEF EXECUTIVE OFFICER JONATHAN KAUFMAN TO STOCKHOLDERS. THE LETTER PROVIDES DETAILED RESPONSES TO FREQUENTLY ASKED QUESTIONS REGARDING THE COMPANY'S RECENT DELISTING FROM THE NASDAQ CAPITAL MARKET, AS WELL AS INSIGHT INTO LIPELLA'S CLINICAL PROGRAMS, FINANCIAL POSITION, AND PLANS TO RELIST ON A NATIONAL EXCHANGE.

LIPELLA PHARMACEUTICALS ISSUES LETTER FROM THE CEO TO STOCKHOLDERS FOLLOWING NASDAQ DELISTING

PITTSBURGH, JUNE 20, 2025 (GLOBE NEWSWIRE) -- LIPELLA PHARMACEUTICALS INC. (OTC: LIPO) (LIPELLA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING THERAPIES FOR DISEASES WITH SIGNIFICANT UNMET NEEDS, TODAY ANNOUNCED THAT THE NASDAQ HEARINGS PANEL HAS DETERMINED TO DELIST THE COMPANY'S COMMON STOCK FROM THE NASDAQ CAPITAL MARKET. TRADING IN THE COMMON STOCK WAS SUSPENDED AT THE OPEN OF BUSINESS TODAY.

LIPELLA PHARMACEUTICALS ANNOUNCES DELISTING FROM NASDAQ CAPITAL MARKET

PITTSBURGH, JUNE 17, 2025 (GLOBE NEWSWIRE) -- LIPELLA PHARMACEUTICALS INC. (NASDAQ: LIPO) (LIPELLA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING THERAPIES FOR DISEASES WITH SIGNIFICANT UNMET NEED, TODAY ANNOUNCED THE ISSUANCE OF U.S. PATENT NO. 12,326,492, TITLED SYSTEMS AND METHODS OF DETECTING INTERSTITIAL CYSTITIS.

LIPELLA PHARMACEUTICALS ANNOUNCES U.S. PATENT ISSUANCE FOR DIAGNOSTIC TECHNOLOGY

SUPPORTS LATE-STAGE DEVELOPMENT AND SCALABLE MANUFACTURING FOR LP-310, A NON-STEROIDAL ORAL RINSE THERAPY FOR ORAL LICHEN PLANUS, A CONDITION WITH NO APPROVED TREATMENTS PITTSBURGH, JUNE 4, 2025  PRISM MEDIAWIRE  LIPELLA PHARMACEUTICALS INC.

LIPELLA PHARMACEUTICALS RE-SIGNS MANUFACTURING COLLABORATION AGREEMENT WITH COOK MYOSITE TO SUPPORT LP-310 CLINICAL DEVELOPMENT

PITTSBURGH, JUNE 04, 2025 (GLOBE NEWSWIRE) -- LIPELLA PHARMACEUTICALS INC. (NASDAQ: LIPO) (LIPELLA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING THERAPIES FOR DISEASES WITH SIGNIFICANT UNMET NEED, TODAY ANNOUNCED THAT IT HAS RE-SIGNED ITS MANUFACTURING COLLABORATION AGREEMENT WITH COOK MYOSITE, INC. (COOK MYOSITE) TO SUPPORT CHEMISTRY, MANUFACTURING AND CONTROL (CMC) DOCUMENTATION SUPPORTING OUR CLINICAL PRODUCTS LP-10 AND LP-310. DR. JONATHAN KAUFMAN, CHIEF EXECUTIVE OFFICER AND CO-FOUNDER OF LIPELLA, SAID, WE ARE PLEASED TO RENEW OUR COLLABORATION WITH COOK MYOSITE, A TRUSTED PARTNER WITH A STRONG TRACK RECORD IN HIGH-QUALITY MANUFACTURING.

STATISTICALLY SIGNIFICANT SAFETY AND EFFICACY DATA FROM 0.25 MG AND 0.50 MG COHORTS TO BE PRESENTED PRESENTATION SCHEDULED FOR THURSDAY, MAY 15, 2025, AT 11:36 A.M. PT PITTSBURGH, MAY 15, 2025  PRISM MEDIAWIRE  LIPELLA PHARMACEUTICALS INC.

LIPELLA PHARMACEUTICALS TO PRESENT PHASE 2A DATA FOR LP-310 IN ORAL LICHEN PLANUS AT 2025 AAOM/EAOM INTERNATIONAL MEETING

STATISTICALLY SIGNIFICANT SAFETY AND EFFICACY DATA FROM 0.25 MG AND 0.50 MG COHORTS TO BE PRESENTED PRESENTATION SCHEDULED FOR THURSDAY, MAY 15, 2025, AT 11:36 A.M. PT PITTSBURGH, MAY 15, 2025 (GLOBE NEWSWIRE) -- LIPELLA PHARMACEUTICALS INC. (NASDAQ: LIPO) (LIPELLA, WE, OUR, OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING THERAPIES FOR DISEASES WITH SIGNIFICANT UNMET NEEDS, TODAY ANNOUNCED THAT TOPLINE DATA FROM THE FIRST TWO DOSE COHORTS OF ITS ONGOING PHASE 2A TRIAL OF LP-310 (LIPOSOMAL TACROLIMUS ORAL RINSE) FOR THE TREATMENT OF ORAL LICHEN PLANUS (OLP) WILL BE PRESENTED AT THE 2025 JOINT INTERNATIONAL MEETING OF THE AMERICAN ACADEMY OF ORAL MEDICINE (AAOM) AND THE EUROPEAN ASSOCIATION OF ORAL MEDICINE (EAOM) IN LAS VEGAS.

JOINT MEETING TO BE HELD IN LAS VEGAS, MAY 14-17 PRESENTATION WILL BE DELIVERED BY DR. ALESSANDRO VILLA OF MIAMI CANCER INSTITUTE TOPLINE STUDY RESULTS DEMONSTRATE CLINICALLY MEANINGFUL IMPROVEMENTS IN OLP VISIBLE LESION RESOLUTION DURING TREATMENT; RETURN TOWARD BASELINE POST-DOSING SUPPORTS LOCALIZED ACTIVITY PITTSBURGH, APRIL 23, 2025 (GLOBE NEWSWIRE) -- LIPELLA PHARMACEUTICALS INC. (NASDAQ: LIPO) ("LIPELLA," "WE," "OUR," OR THE "COMPANY"), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING THERAPIES FOR DISEASES WITH SIGNIFICANT UNMET NEEDS, TODAY ANNOUNCED THAT ITS ABSTRACT ON LP-10 FOR THE TREATMENT OF ORAL LICHEN PLANUS (OLP) HAS BEEN ACCEPTED FOR PODIUM PRESENTATION AT THE 2025 JOINT INTERNATIONAL MEETING OF THE AMERICAN ACADEMY OF ORAL MEDICINE (AAOM) AND EUROPEAN ASSOCIATION OF ORAL MEDICINE (EAOM). THE MEETING WILL TAKE PLACE MAY 1417 IN LAS VEGAS.

LIPELLA PHARMACEUTICALS ABSTRACT ON ORAL LICHEN PLANUS TREATMENT ACCEPTED FOR PODIUM PRESENTATION AT 2025 AAOM/EAOM INTERNATIONAL MEETING CONFERENCE ON GLOBAL TRANSFORMATION IN ORAL MEDICINE

LISTEN: PITTSBURGH, APRIL 23, 2025  PRISM MEDIAWIRE  LIPELLA PHARMACEUTICALS INC.

LISTEN: PITTSBURGH, APRIL 22, 2025  PRISM MEDIAWIRE  LIPELLA PHARMACEUTICALS INC. (NASDAQ: LIPO) (LIPELLA, OUR, US, OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADDRESSING SERIOUS DISEASES WITH SIGNIFICANT UNMET NEEDS, TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE SECOND COHORT (0.

Lipella Pharmaceuticals Inc.

LIPO

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Lipella Pharmaceuticals Inc.

LIPO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

LIPO